Long-Term Organ Damage: Anifrolumab versus Real-World Standard of Care in Adult Patients with Active Systemic Lupus Erythematosus - LASER

Study identifier:D3461R00077

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Long-Term Organ Damage: Anifrolumab versus Real-World Standard of Care in Adult Patients with Active Systemic Lupus Erythematosus (LASER) An External Comparator Arm Study for the TULIP Trials Using the University of Toronto Lupus Clinic Cohort

Medical condition

Long-Term Organ Damage in Adult Patients with Active Systemic Lupus Erythematosus

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

478

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 09 May 2024
Estimated Primary Completion Date: 31 Oct 2024
Estimated Study Completion Date: 31 Oct 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jun 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

IQVIA Ltd, University Health Network

Inclusion and exclusion criteria